# The Efficacy and Safety of HRS-4029 in Acute Ischemic Stroke Patients

> **NCT07739160** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Beijing Suncadia Pharmaceuticals Co., Ltd** · enrollment: 340 (estimated)

## Conditions studied

- Acute Ischemic Stroke

## Interventions

- **DRUG:** HRS-4029
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07739160
- **Lead sponsor:** Beijing Suncadia Pharmaceuticals Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10
- **Primary completion:** 2027-04
- **Final completion:** 2027-07
- **Target enrollment:** 340 (ESTIMATED)
- **Last updated:** 2026-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07739160

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07739160, "The Efficacy and Safety of HRS-4029 in Acute Ischemic Stroke Patients". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07739160. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*